Protocol Ledger

NCT07919678 · Phase III · RECRUITING

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

Interventional Phase III clinical trial protocol NCT07919678 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-10-26 Enrollment: 656 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07919678
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)656 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07919678
Protocol FieldVerified Registry Value
NCT IdentifierNCT07919678
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment656 participants (ESTIMATED)
Registered Start Date2026-10-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07919678
Hospital Research SiteLocationSite Profile
Renstar Medical ResearchOcala, FLOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI